Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
21 févr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
21 oct. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Findings presented at the annual Fall Clinical Dermatology ConferenceSurvey found that path to diagnosis for people with seborrheic dermatitis (average of 3.6 years) substantially longer than...
New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
09 sept. 2022 08h15 HE
|
Arcutis Biotherapeutics, Inc.
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle...
New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
06 sept. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
06 juin 2022 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle...
CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
25 mai 2022 10h33 HE
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S.Survey found that, among adults with seborrheic dermatitis who use treatments, only...
Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
25 mai 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S.Survey found that, among adults with seborrheic dermatitis who use treatments,...
Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
25 mars 2022 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Previously reported data demonstrated that roflumilast foam provided statistically significant improvement in disease severity and a favorable safety and tolerability profileImprovement on...
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
01 févr. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023A total of 457 subjects are enrolled in the STRATUM studySeborrheic dermatitis affects 10...
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
12 juil. 2021 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...